Bob Gantzer
@bob-gantzer.bsky.social
Lab technology enthusiast, mainly robotics. Chicago sports fan. Enjoys fishing, but rarely catches anything.
I am here to see if Lab Automation Bluesky is a thing, so here we go…
Benchling released their 2024 “State of Tech in Biopharma” report last week (great report, would recommend).
One of the takeaways I noticed immediately was the decline in sentiment towards lab automation from 2023.
Benchling released their 2024 “State of Tech in Biopharma” report last week (great report, would recommend).
One of the takeaways I noticed immediately was the decline in sentiment towards lab automation from 2023.
November 25, 2024 at 11:40 PM
I am here to see if Lab Automation Bluesky is a thing, so here we go…
Benchling released their 2024 “State of Tech in Biopharma” report last week (great report, would recommend).
One of the takeaways I noticed immediately was the decline in sentiment towards lab automation from 2023.
Benchling released their 2024 “State of Tech in Biopharma” report last week (great report, would recommend).
One of the takeaways I noticed immediately was the decline in sentiment towards lab automation from 2023.
#LabAutomation community, any thoughts on the recent @benchling tech report? My biggest takeaway was the significant drop in investment sentiment from 2023 to 2024. Thoughts on why this is?
November 21, 2024 at 5:56 PM
#LabAutomation community, any thoughts on the recent @benchling tech report? My biggest takeaway was the significant drop in investment sentiment from 2023 to 2024. Thoughts on why this is?